Methyclothiazide_product_DataBase

Bioactivity

Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715). Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro[1][2][3].

Target

IC50: voltage-dependent Ca-channel (VDCC)

Invitro

Methyclothiazide (0-100 μM) induces endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP only in aortas from SHR, and the maximal vasoconstrictive effect of Norepinephrine (HY-13715) and arginine vasopressin (AVP) is decreased by 59% and 32.3 %, respectively[1]. Methyclothiazide (0-100 μM) induces inhibitory effect on the contractile response to Norepinephrine (HY-13715) is abolished by N-nitro-L-arginine (NOLA) but not indomethacin[1]. Methyclothiazide (100 μM) affects the vascular responses to extracellular Ca2+ under high-K+ depolarizing conditions. It can reduce Ca2+ contracture in a high-K+, Ca2+-free solution. The maximal contracture is reduced by 90.4%[1].

Name

Methyclothiazide

CAS

135-07-9

Formula

C9H11Cl2N3O4S2

Molar Mass

360.24

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Colas, B., et al., Mechanisms of methyclothiazide-induced inhibition of contractile responses in rat aorta. Eur J Pharmacol, 2000. 408(1): p. 63-7. [2]. Colas, B., et al., Direct vascular actions of methyclothiazide and indapamide in aorta of spontaneously hypertensive rats. Fundam Clin Pharmacol, 2000. 14(4): p. 363-8. [3]. Sasaki, S. and R.D. Bunag, Methyclothiazide attenuates salt-induced hypertension without affecting sympathetic responsiveness in Dahl rats. J Cardiovasc Pharmacol, 1983. 5(3): p. 378-83.

PeptideDB

Methyclothiazide

CAS: 135-07-9 F: C9H11Cl2N3O4S2 W: 360.24